New Logo July 12, 2022.png
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
28 sept. 2022 08h30 HE | Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
26 sept. 2022 09h00 HE | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Qu Biologics.png
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
26 sept. 2022 08h00 HE | Qu Biologics, Inc.
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy...
Aviv-Clinic Logo.png
New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome
23 sept. 2022 13h51 HE | Aviv Clinics
ORLANDO, Fla., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Today, Aviv Clinics highlights a new study published in Scientific Reports showing an effective treatment to heal damaged brain tissue and relieve...
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
22 sept. 2022 09h00 HE | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
22 sept. 2022 08h00 HE | Vir Biotechnology, Inc.
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes
22 sept. 2022 07h46 HE | SciSparc Ltd
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
LOGO roboto color with gray.png
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
15 sept. 2022 15h23 HE | Folia Health
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
12 sept. 2022 08h00 HE | Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
10 sept. 2022 12h30 HE | Ivy Brain Tumor Center
Phoenix, AZ, Sept. 10, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced today initial results from a Phase 0 clinical trial of pamiparib in...